Elesclomol
Based on 117 publication(s) in Google Scholar
Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research.
For research use only. We do not sell to patients.
- Purity: 99.19%
- CAS No.: 488832-69-5
- Formula: C19H20N4O2S2
- Molecular Weight:400.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Elesclomol
More- Cancer Cell. 2025 Apr 7:S1535-6108(25)00132-1. [Abstract]
- Cancer Cell. 2025 May 12;43(5):937-954.e9. [Abstract]
- Cell. 2026 Jun 22:S0092-8674(26)00636-7. [Abstract]
- Cell. 2026 Mar 31:S0092-8674(26)00279-5. [Abstract]
- Nat Immunol. 2025 Oct;26(10):1660-1672. [Abstract]
- Exploration. 2026 Mar 19.
- Sci Bull. 2025 May 16:S2095-9273(25)00531-6. [Abstract]
- ACS Nano. 2025 Oct 21;19(41):36701-36717. [Abstract]
- ACS Nano. 2025 Jun 24;19(24):21969-21982. [Abstract]
- ACS Nano. 2025 Feb 11;19(5):5429-5446. [Abstract]
- Nat Commun. 2026 Feb 25;17(1):3142. [Abstract]
- Nat Commun. 2025 Jul 1;16(1):6016. [Abstract]
- Cell Death Differ. 2025 Dec 19. [Abstract]
- Cell Death Differ. 2024 Nov;31(11):1452-1466. [Abstract]
- Adv Sci (Weinh). 2025 Nov 7:e18323. [Abstract]
- Adv Sci (Weinh). 2025 Feb 20:e2408106. [Abstract]
- Adv Sci (Weinh). 2024 Dec 5:e2413408. [Abstract]
- Adv Sci (Weinh). 2024 Jun 10:e2401396. [Abstract]
- Nat Chem Biol. 2019 Jul;15(7):681-689. [Abstract]
- Chem Eng J. 2025 Nov 3.
- Chem Eng J. 2025 Sep 15.
- Biomaterials. 2024 Aug 17:313:122762. [Abstract]
- J Exp Clin Cancer Res. 2025 May 17;44(1):149. [Abstract]
- J Exp Clin Cancer Res. 2023 Jun 6;42(1):142. [Abstract]
- Int J Oral Sci. 2026 Feb 3;18(1):13. [Abstract]
- Mol Ther. 2025 Sep 10:S1525-0016(25)00732-4. [Abstract]
- Redox Biol. 2025 Jun 7:85:103722. [Abstract]
- J Hazard Mater. 2025 Dec 30:502:140998. [Abstract]
- J Hazard Mater. 2024 Jul 31:477:135391. [Abstract]
- Nano Today. 2024 Jun, 56, 102223.
- Research (Wash D C). 2025 May 23:8:0703. [Abstract]
- MedComm (2020). 2024 Aug 12;5(8):e684. [Abstract]
- J Immunother Cancer. 2025 Jun 8;13(6):e011472. [Abstract]
- Cell Rep Med. 2024 May 21;5(5):101523. [Abstract]
- Cell Rep Med. 2022 Nov 15;3(11):100802. [Abstract]
- Pharmacol Res. 2025 Apr 16:107739. [Abstract]
- Mater Today Bio. 2026 Mar 10:37:103021. [Abstract]
- Mater Today Bio. 2024 Nov 9:29:101326. [Abstract]
- Adv Healthc Mater. 2025 Oct 2:e02769. [Abstract]
- Acta Biomater. 2025 Aug:202:463-475. [Abstract]
- Cell Death Dis. 2025 Apr 19;16(1):316. [Abstract]
- Genes Dis. 2026 Mar 17.
- Phytomedicine. 2025 Oct:146:157091. [Abstract]
- Free Radic Biol Med. 2026 Mar 25:250:399-410. [Abstract]
- NPJ Precis Oncol. 2025 Jul 8;9(1):230. [Abstract]
- Biomed Pharmacother. 2024 Sep 11:179:117415. [Abstract]
- Biomed Pharmacother. 2024 May 10:175:116727. [Abstract]
- Biomed Pharmacother. 2023 Mar:159:114301. [Abstract]
- J Transl Med. 2023 Jan 16;21(1):28. [Abstract]
- Oncogene. 2026 Mar;45(9):840-855. [Abstract]
- Oncogene. 2025 Dec 16. [Abstract]
- Oncogene. 2025 Apr 16. [Abstract]
- Oncogene. 2024 Sep;43(40):2971-2985. [Abstract]
- Cell Death Discov. 2026 Jan 9;12(1):12. [Abstract]
- Cell Death Discov. 2025 Apr 25;11(1):197. [Abstract]
- Anal Chem. 2026 Mar 10. [Abstract]
- Mol Med. 2025 Apr 4;31(1):126. [Abstract]
- Cell Biosci. 2022 Dec 29;12(1):209. [Abstract]
- JCI Insight. 2025 Nov 24;10(22):e187448. [Abstract]
- Cancer Cell Int. 2025 Nov 5;25(1):388. [Abstract]
- Biomater Adv. 2025 Oct 11:180:214552. [Abstract]
- Transl Res. 2024 May 24:S1931-5244(24)00107-5. [Abstract]
- Front Immunol. 2022 Oct 6:13:948042. [Abstract]
- Colloids Surf B Biointerfaces. 2025 Apr 9:252:114682. [Abstract]
- World J Gastroenterol. 2025 Sep 14;31(34):109825. [Abstract]
- Commun Biol. 2025 Dec 18;8(1):1783. [Abstract]
- Life Sci. 2023 Nov 1:332:122081. [Abstract]
- Biofactors. 2024 Sep-Oct;50(5):1009-1023. [Abstract]
- Int J Oncol. 2025 May;66(5):38. [Abstract]
- Pharmaceuticals (Basel). 2024 May 24;17(6):678. [Abstract]
- Biomolecules. 2019 Jul 24;9(8):298. [Abstract]
- Int Immunopharmacol. 2025 Dec 21:170:116092. [Abstract]
- Int Immunopharmacol. 2024 Nov 2;143(Pt 3):113546. [Abstract]
- Int Immunopharmacol. 2024 Jun 15:134:112159. [Abstract]
- J Cell Mol Med. 2025 Dec;29(24):e70968. [Abstract]
- J Inflamm Res. 2025 May 22:18:6607-6622. [Abstract]
- J Mater Sci. 2026 Jan 16;61(7):4653-4667.
- Int Dent J. 2026 Mar 20;76(3):109506. [Abstract]
- PLoS Genet. 2026 Jan 23;22(1):e1012013. [Abstract]
- Heliyon. 2024 Jul 14;10(14):e34586. [Abstract]
- Heliyon. 2023 Mar 16;9(4):e14613. [Abstract]
- Eur J Med Res. 2025 Dec 30;31(1):170. [Abstract]
- Front Oncol. 2024; 14: 1409620.. [Abstract]
- Int J Med Sci. 2026 Feb 26;23(4):1243-1256. [Abstract]
- Funct Integr Genomics. 2026 Jan 27;26(1):32. [Abstract]
- Arch Biochem Biophys. 2025 Oct 29:775:110651. [Abstract]
- Breast Cancer Res Treat. 2025 Jun;211(2):467-478. [Abstract]
- Free Radic Res. 2026 Jun 10:1-12. [Abstract]
- Discov Oncol. 2024 May 26;15(1):187. [Abstract]
- J Appl Toxicol. 2023 Aug;43(8):1214-1224. [Abstract]
- Prostate. 2025 Oct 1. [Abstract]
- Cell Biochem Biophys. 2024 Sep;82(3):2687-2699. [Abstract]
- Gene. 2024 Apr 15:902:148156. [Abstract]
- Oncol Lett. 2025 May 19;30(1):353. [Abstract]
- Biochem Biophys Res Commun. 2024 Dec 10:737:150926. [Abstract]
- Biochem Biophys Res Commun. 2024 Nov 26:735:150804. [Abstract]
- Biochem Biophys Res Commun. 2024 Jul 2:730:150341. [Abstract]
- Biochem Genet. 2025 Jun;63(3):2548-2578. [Abstract]
- Curr Med Sci. 2025 Aug;45(4):831-840. [Abstract]
- J Int Med Res. 2023 Dec;51(12):3000605231213435. [Abstract]
- Curr Med Sci. 2023 Jun;43(3):526-538. [Abstract]
- Mol Biol. 2026 Mar 10.
- bioRxiv. 2026 Jan 29:2026.01.27.702014. [Abstract]
- bioRxiv. 2025 Nov 19:2025.11.19.688750. [Abstract]
- Res Sq. 2025 May 05.
- SSRN. 2025 Feb 14.
- Res Sq. 2024 Aug 19.
- bioRxiv. 2018 Mar 24.
- Research Square Preprint. 2023 Dec 13.
- Research Square Preprint. 2023 Nov 14.
- Research Square Preprint. 2023 Jun 9.
- Research Square Print. 2023 Mar 14.
- Patent. US20220023240A1.
- bioRxiv. March 24, 2018.
- Patent. US9808434B2.
- Patent. US20160354327A1.
- Bilkent University. 2014 Aug.
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
IF
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.1 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 23937981] |
| DU-145 | IC50 |
0.02 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 23937981] |
| HL-60 | IC50 |
0.05 μM
Compound: 1s, STA-4783
|
Cytotoxicity against multidrug-resistant human HL60 cells
Cytotoxicity against multidrug-resistant human HL60 cells
|
[PMID: 23937981] |
| HL-60 | IC50 |
0.4 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
|
[PMID: 23937981] |
| MDA-MB-435 | IC50 |
5 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human MDA435 cells
Cytotoxicity against human MDA435 cells
|
[PMID: 23937981] |
| MES-SA | IC50 |
0.005 μM
Compound: 1s, STA-4783
|
Cytotoxicity against multidrug-resistant human MES-SA cells
Cytotoxicity against multidrug-resistant human MES-SA cells
|
[PMID: 23937981] |
| MES-SA | IC50 |
0.05 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human MES-SA cells
Cytotoxicity against human MES-SA cells
|
[PMID: 23937981] |
| MES-SA/Dx5 | IC50 |
0.005 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human MES-SA/Dx5 cells
Cytotoxicity against human MES-SA/Dx5 cells
|
[PMID: 23937981] |
| PBMC | IC50 |
>10 μM
Compound: 1s, STA-4783
|
Cytotoxicity against human PBMC cells
Cytotoxicity against human PBMC cells
|
[PMID: 23937981] |
| Ramos | EC50 |
0.02 μM
Compound: 1s, STA-4783
|
Induction of Hsp70 production in human Ramos cells after 5 hrs by ELISA
Induction of Hsp70 production in human Ramos cells after 5 hrs by ELISA
|
[PMID: 23937981] |
Elesclomol (STA-4783) binds the FDX1 α2/α3 helices and β5 strand, but does not bind the paralog protein FDX2. Elesclomol-Cu(II) is an FDX1 neo-substrate. FDX1 protein binds and reduces the elesclomol-Cu(II) complex[1].
Elesclomol-Cu (1:1 ratio) (40 nM) for only 2 hours results in a 15- to 60-fold increase in intracellular copper levels that triggered cell death more than 24 hours later in ABC1 cells[1].
The addition of copper to elesclomol at a 1:1 molar ratio prior to treatment significantly reduces cell viability when cells are grown in glycolytic (glucose media) conditions[2].
Elesclomol (200 nM; 18 hours) treatment increases the number of early and late apoptotic cells in HSB2 cells. Elesclomol induces apoptosis in cancer cells through the induction of oxidative stress[3].
Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 cells with IC50 values of 110 nM, 24 nM and 9 nM, respectively[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HSB2 cells
-
Concentration:200 nM
-
Incubation Time:18 hours
-
Result:Increased the number of early and late apoptotic cells.
Elesclomol escorted copper to the mitochondria and increased cytochrome c oxidase levels in the brain. Elesclomol prevents detrimental neurodegenerative changes and improved the survival of the mottled-brindled mouse[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cardiac Ctr1 knockout mice[4]
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection; every three days from post-natal day 5 to 26 and once weekly until post-natal day 54
-
Result:Ameliorated severe cardiac pathology with a partial reduction in hypertrophy.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 488832-69-5
-
Appearance Solid
-
Molecular Weight 400.52
-
Formula C19H20N4O2S2
-
Color Light yellow to yellow
-
SMILES
S=C(C1=CC=CC=C1)N(NC(CC(NN(C(C2=CC=CC=C2)=S)C)=O)=O)C
-
Synonyms
STA-4783
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (117)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. [Abstract]2025 Apr 7:S1535-6108(25)00132-1. PMID: 40215978 -
Cancer Cell
2025 May 12;43(5):937-954.e9. PMID: 40054467 -
Cell
2026 Jun 22:S0092-8674(26)00636-7. PMID: 42330950 -
Cell
2026 Mar 31:S0092-8674(26)00279-5. PMID: 41923640 -
Nat Immunol
Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. [Abstract]2025 Oct;26(10):1660-1672. PMID: 40954252 -
-
Sci Bull
2025 May 16:S2095-9273(25)00531-6. PMID: 40473539 -
ACS Nano
A CRISPR-Customizable Copper-Coordinated DNA Nanoplatform Potentiates Cuproptosis Through Circadian and Metabolic Pathway Manipulation. [Abstract]2025 Oct 21;19(41):36701-36717. PMID: 41071600 -
ACS Nano
Enhanced Cuproptosis via Metabolic Reprogramming Using Copper-Delivering Co-N-C Single-Atom Nanozyme. [Abstract]2025 Jun 24;19(24):21969-21982. PMID: 40499169 -
ACS Nano
Cuproptosis-Inducing Functional Nanocomposites for Enhanced and Synergistic Cancer Radiotherapy. [Abstract]2025 Feb 11;19(5):5429-5446. PMID: 39895200 -
Nat Commun
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [Abstract]2026 Feb 25;17(1):3142. PMID: 41735312 -
Nat Commun
2025 Jul 1;16(1):6016. PMID: 40593722 -
Cell Death Differ
2025 Dec 19. PMID: 41420103 -
Cell Death Differ
2024 Nov;31(11):1452-1466. PMID: 38987382 -
Adv Sci (Weinh)
Fe-S Protein FDX1 Triggers Tumor-Intrinsic Innate Immunity via Mitochondrial Nucleic Acids Release to Orchestrate Ferroptosis in CCRCC. [Abstract]2025 Nov 7:e18323. PMID: 41199656 -
Adv Sci (Weinh)
AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple-Negative Breast Cancer. [Abstract]2025 Feb 20:e2408106. PMID: 39976173 -
Adv Sci (Weinh)
2024 Dec 5:e2413408. PMID: 39639737 -
Adv Sci (Weinh)
Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death. [Abstract]2024 Jun 10:e2401396. PMID: 38859590 -
Nat Chem Biol
2019 Jul;15(7):681-689. PMID: 31133756
Elesclomol purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2019 Jul;15(7):681-689. [Abstract]
The viability of 724 barcoded cell lines was determined for 8 concentrations of elesclomol and the calculated area under the curve (AUC) is presented as box plot for different lineages.Elesclomol is very potent in inducing cell death across all lineages with most cells showing sensitivity at doses above 100nM.
Elesclomol purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2019 Jul;15(7):681-689. [Abstract]
The viability of T47D cells cultured in the presence of galactose (Hi-Mito state) was examined following the addition of either elesclomol in the presence or absence of the copper chelator tetrathiomolybdate (TTM) at 10uM concentration.
-
-
-
Biomaterials
pH-responsive and nanoenzyme-loaded artificial nanocells relieved osteomyelitis efficiently by synergistic chemodynamic and cuproptosis therapy. [Abstract]2024 Aug 17:313:122762. PMID: 39178559 -
J Exp Clin Cancer Res
Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation. [Abstract]2025 May 17;44(1):149. PMID: 40382627 -
J Exp Clin Cancer Res
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. [Abstract]2023 Jun 6;42(1):142. PMID: 37277863 -
Int J Oral Sci
2026 Feb 3;18(1):13. PMID: 41629272 -
Mol Ther
Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. [Abstract]2025 Sep 10:S1525-0016(25)00732-4. PMID: 40931516 -
Redox Biol
LncRNA PVT1 promotes cuproptosis through transcriptional activation of FDX1 in colorectal cancer. [Abstract]2025 Jun 7:85:103722. PMID: 40505346 -
J Hazard Mater
Copper overload induces lifespan shortening through activating mitochondrial respiration in Caenorhabditis elegans. [Abstract]2025 Dec 30:502:140998. PMID: 41483520 -
J Hazard Mater
2024 Jul 31:477:135391. PMID: 39106724
Elesclomol purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2024 Jul 31:477:135391. [Abstract]
Elesclomol (20-80 nM; 6-24 h) with copper (ES/Cu) promotes cell death in a dose-dependent manner and cell growth in GCs.(b) Cell viability of ovarian granulosa cells under concentration gradients of 3-NP, Cu and ES, with a dashed line indicating the inhibition rate of 50% (IC50); (e) The survival ratio of mGCs treated with 40nM ES or 10μM TTM and exposed to a copper concentration gradient was assessed by CCK-8 assay.
-
-
Research (Wash D C)
Targeting the Exonic Circular OGT RNA/O-GlcNAc Transferase/Forkhead Box C1 Axis Inhibits Asparagine- and Alanine-Mediated Ferroptosis Repression in Neuroblastoma Progression. [Abstract]2025 May 23:8:0703. PMID: 40416363 -
MedComm (2020)
Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. [Abstract]2024 Aug 12;5(8):e684. PMID: 39135915 -
J Immunother Cancer
C5a/C5aR pathway blocking promoted CuS-mediated cancer therapy effect by inhibiting cuproptosis resistance. [Abstract]2025 Jun 8;13(6):e011472. PMID: 40484643 -
Cell Rep Med
Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. [Abstract]2024 May 21;5(5):101523. PMID: 38670098 -
Cell Rep Med
Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. [Abstract]2022 Nov 15;3(11):100802. PMID: 36334593 -
Pharmacol Res
Sirtuin3 attenuates pressure overload-induced pathological myocardial remodeling by inhibiting cardiomyocyte cuproptosis. [Abstract]2025 Apr 16:107739. PMID: 40250507 -
Mater Today Bio
PKA activation rescues myocardial injury elicited by silica nanoparticles through improving oxidative stress, mitochondrial health, and copper homeostasis. [Abstract]2026 Mar 10:37:103021. PMID: 41890951 -
Mater Today Bio
Orchestrated copper-loaded nanoreactor for simultaneous induction of cuproptosis and immunotherapeutic intervention in colorectal cancer. [Abstract]2024 Nov 9:29:101326. PMID: 39606425 -
Adv Healthc Mater
YAP Expression Confers Therapeutic Vulnerability to Cuproptosis in Breast Cancer Cells by Regulating Copper Homeostasis. [Abstract]2025 Oct 2:e02769. PMID: 41039751 -
Acta Biomater
A tumor microenvironment-responsive nanocomposite for enhanced copper retention and hypoxia reversal to promote cuproptosis in tumor treatment. [Abstract]2025 Aug:202:463-475. PMID: 40618974 -
Cell Death Dis
Endoplasmic reticulum stress related super-enhancers suppress cuproptosis via glycolysis reprogramming in lung adenocarcinoma. [Abstract]2025 Apr 19;16(1):316. PMID: 40253387 -
-
Phytomedicine
Columbianadin targets TRIM7 to maintain P2X7 palmitoylation, inhibiting cuproptosis in synovial M2 macrophages. [Abstract]2025 Oct:146:157091. PMID: 40768810 -
Free Radic Biol Med
2026 Mar 25:250:399-410. PMID: 41895414 -
NPJ Precis Oncol
2025 Jul 8;9(1):230. PMID: 40629130 -
Biomed Pharmacother
Baicalein enhances cisplatin sensitivity in cervical cancer cells by promoting cuproptosis through the Akt pathway. [Abstract]2024 Sep 11:179:117415. PMID: 39265236 -
Biomed Pharmacother
Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes. [Abstract]2024 May 10:175:116727. PMID: 38733771 -
Biomed Pharmacother
4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. [Abstract]2023 Mar:159:114301. PMID: 36706634 -
J Transl Med
EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma. [Abstract]2023 Jan 16;21(1):28. PMID: 36647156 -
Oncogene
PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction. [Abstract]2026 Mar;45(9):840-855. PMID: 41673093 -
Oncogene
2025 Dec 16. PMID: 41402633 -
Oncogene
FDX1 promotes elesclomol-induced PANoptosis in diffuse large B-cell lymphoma via activating IRF3/IFN-β signaling. [Abstract]2025 Apr 16. PMID: 40240522 -
Oncogene
m6A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis. [Abstract]2024 Sep;43(40):2971-2985. PMID: 39198615 -
Cell Death Discov
FDX1-mediated cuproptosis promotes cholestatic liver injury exacerbated by taurocholic acid-enhanced copper accumulation. [Abstract]2026 Jan 9;12(1):12. PMID: 41513631 -
Cell Death Discov
Single-cell multi-omics elucidates the role of RPS27-RPS24 fusion gene in osteosarcoma chemoresistance and metabolic regulation. [Abstract]2025 Apr 25;11(1):197. PMID: 40280903 -
Anal Chem
Systematic and Quantitative Investigation of Newly Synthesized Proteins Reveals Distinct Ion Homeostasis and Mitochondrial Changes between Cuproptosis and Ferroptosis in Human Cells. [Abstract]2026 Mar 10. PMID: 41804563 -
Mol Med
Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. [Abstract]2025 Apr 4;31(1):126. PMID: 40186145 -
Cell Biosci
A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. [Abstract]2022 Dec 29;12(1):209. PMID: 36581992 -
JCI Insight
Mitochondrial metabolic rewiring sensitizes mTORC1 inhibitor persister cells to cuproptosis. [Abstract]2025 Nov 24;10(22):e187448. PMID: 41277553 -
Cancer Cell Int
Prognostic evaluation and experimental validation of cuproptosis-related hub genes identified through weighted gene co-expression network analysis in uveal melanoma. [Abstract]2025 Nov 5;25(1):388. PMID: 41194198 -
Biomater Adv
PD-L1 nanobody-engineered bacterial outer membrane vesicles delivering cuproptosis micelles for potentiated cancer immunotherapy. [Abstract]2025 Oct 11:180:214552. PMID: 41092615 -
Transl Res
2024 May 24:S1931-5244(24)00107-5. PMID: 38797432 -
Front Immunol
Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma. [Abstract]2022 Oct 6:13:948042. PMID: 36275737 -
Colloids Surf B Biointerfaces
Multi-pathway copper metabolisms regulation based on an engineered copper/ferrous nanoplatform for enhanced tumor cuproptosis therapy. [Abstract]2025 Apr 9:252:114682. PMID: 40215641 -
World J Gastroenterol
B cell CLL/lymphoma 10 promotes colorectal cancer cell proliferation and regulates cuproptosis sensitivity through the NF-κB signaling pathway. [Abstract]2025 Sep 14;31(34):109825. PMID: 40937457 -
Commun Biol
TRIM21 promotes K63-linked ubiquitination of ALKBH5 and suppresses cuproptosis via down-regulation of LIAS in esophageal squamous cell carcinoma. [Abstract]2025 Dec 18;8(1):1783. PMID: 41413718 -
Life Sci
Multi-omics analysis defines a cuproptosis-related prognostic model for ovarian cancer: Implication of WASF2 in cuproptosis resistance. [Abstract]2023 Nov 1:332:122081. PMID: 37717621 -
Biofactors
SP1/CTR1-mediated oxidative stress-induced cuproptosis in intervertebral disc degeneration. [Abstract]2024 Sep-Oct;50(5):1009-1023. PMID: 38599595 -
Int J Oncol
Targeting the cuproptosis‑associated gene COL22A1 in glioblastoma using EMD‑1204831 and kaempferol. [Abstract]2025 May;66(5):38. PMID: 40242972 -
Pharmaceuticals (Basel)
Improved Immunotherapy Outcomes via Cuproptosis Upregulation of HLA-DRA Expression: Promoting the Aggregation of CD4+ and CD8+T Lymphocytes in Clear Cell Renal Cell Carcinoma. [Abstract]2024 May 24;17(6):678. PMID: 38931345 -
Biomolecules
The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria. [Abstract]2019 Jul 24;9(8):298. PMID: 31344923
Elesclomol purchased from MedChemExpress. Usage Cited in: Biomolecules. 2019 Jul 24;9(8):298. [Abstract]
Confocal images of MitoSOX fluorescence intensity in CV-1 cells at the 20-min time point after E:C (elesclomol:copper)- treatment in the presence and absence of the mitochondrial superoxide scavenger MitoTEMPO.
-
Int Immunopharmacol
Hepatocyte cuproptosis promotes the progression of hepatic fibrosis: Emerging a potential therapeutic target. [Abstract]2025 Dec 21:170:116092. PMID: 41429062 -
Int Immunopharmacol
Quercetin Protects against Silicon dioxide Particles-induced spleen ZBP1-Mediated PANoptosis by regulating the Nrf2/Drp1/mtDNA axis. [Abstract]2024 Nov 2;143(Pt 3):113546. PMID: 39488923 -
Int Immunopharmacol
Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis. [Abstract]2024 Jun 15:134:112159. PMID: 38692018 -
J Cell Mol Med
Identification of Glutathione Synthetase as a Therapeutic Target for Cervical Cancer via Combining Bioinformatics and Experimental Validation. [Abstract]2025 Dec;29(24):e70968. PMID: 41431124 -
J Inflamm Res
MiR-133a-5p Facilitates Cuproptosis in Hepatocellular Carcinoma Through Targeting of ATP7B. [Abstract]2025 May 22:18:6607-6622. PMID: 40433054 -
-
Int Dent J
MT2A-Mediated Regulation of Cuproptosis in Human Dental Pulp Cells Modulates Macrophage M1 Polarization in Pulpitis. [Abstract]2026 Mar 20;76(3):109506. PMID: 41863975 -
PLoS Genet
A C. elegans model of copper deficiency: Dietary interventions rescue CTR1/CHCA-1 copper transporter mutant phenotype. [Abstract]2026 Jan 23;22(1):e1012013. PMID: 41575937 -
Heliyon
A cuproptosis-related lncRNAs signature predicts prognosis and reveals pivotal interactions between immune cells in colon cancer. [Abstract]2024 Jul 14;10(14):e34586. PMID: 39114018 -
Heliyon
A novel cuproptosis-related gene signature for overall survival prediction in uterine corpus endometrial carcinoma (UCEC). [Abstract]2023 Mar 16;9(4):e14613. PMID: 37035374 -
Eur J Med Res
DACT1 inhibits cuproptosis and promotes cell malignancy via activation of PI3K/AKT signaling in laryngeal squamous cell carcinoma. [Abstract]2025 Dec 30;31(1):170. PMID: 41469752 -
Front Oncol
The signature genes of cuproptosis associates with tumor immune microenvironment and predicts prognosis in kidney renal clear cell carcinoma. [Abstract]2024; 14: 1409620.. PMID: 39206152 -
Int J Med Sci
IDH1 mutation creates a dependency on fatty acid metabolism that underlies sensitivity to cuproptosis in acute myeloid leukemia cells. [Abstract]2026 Feb 26;23(4):1243-1256. PMID: 41938504 -
Funct Integr Genomics
GCSH promotes colorectal cancer progression by inhibiting Cuproptosis through the PI3K/AKT-FDX1 axis. [Abstract]2026 Jan 27;26(1):32. PMID: 41591502 -
Arch Biochem Biophys
SIRT7 deficiency promoted cuproptosis-mediated mitochondrial dysfunction and inhibited malignant development of cervical cancer. [Abstract]2025 Oct 29:775:110651. PMID: 41167446 -
Breast Cancer Res Treat
2025 Jun;211(2):467-478. PMID: 40055251 -
Free Radic Res
Acidic plasma-activated povidone-iodine induces copper-dependent oxidative death in oral squamous cell carcinoma cells. [Abstract]2026 Jun 10:1-12. PMID: 42253274 -
Discov Oncol
Bioinformatics analysis and experimental validation of m6A and cuproptosis-related lncRNA NFE4 in clear cell renal cell carcinoma. [Abstract]2024 May 26;15(1):187. PMID: 38797784 -
J Appl Toxicol
Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. [Abstract]2023 Aug;43(8):1214-1224. PMID: 36861143 -
Prostate
LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway. [Abstract]2025 Oct 1. PMID: 41031841 -
Cell Biochem Biophys
Quercetin Attenuates Acute Kidney Injury Caused by Cisplatin by Inhibiting Ferroptosis and Cuproptosis. [Abstract]2024 Sep;82(3):2687-2699. PMID: 39026057 -
Gene
Cuproptosis/OXPHOS Tendency Prediction of Prognosis and Immune Microenvironment of Esophageal Squamous Cell Carcinoma: Bioinformatics Analysis and Experimental Validation. [Abstract]2024 Apr 15:902:148156. PMID: 38211899 -
Oncol Lett
Role of the SPI1/CDKN2A/p53 signaling pathway in cuproptosis of lung adenocarcinoma cells. [Abstract]2025 May 19;30(1):353. PMID: 40438868 -
Biochem Biophys Res Commun
Overexpression of MCL1 attenuates irritable bowel syndrome by regulating cuproptosis: Screening and validation. [Abstract]2024 Dec 10:737:150926. PMID: 39488085 -
Biochem Biophys Res Commun
Inhibition of CTR1 expression improves hypoxia/reoxygenation-induced myoblast injury by blocking cuproptosis. [Abstract]2024 Nov 26:735:150804. PMID: 39418771 -
Biochem Biophys Res Commun
S-Allyl-L-cysteine (SAC) inhibits copper-induced apoptosis and cuproptosis to alleviate cardiomyocyte injury. [Abstract]2024 Jul 2:730:150341. PMID: 39018965 -
Biochem Genet
Bioinformatics Identification and Experimental Validation of a Prognostic Model for the Survival of Lung Squamous Cell Carcinoma Patients. [Abstract]2025 Jun;63(3):2548-2578. PMID: 38806973 -
Curr Med Sci
Dapagliflozin Suppressed Cuproptosis and Myocardial Fibrosis in Myocardial Infarction Through HIF-1α/TGF-β Pathway. [Abstract]2025 Aug;45(4):831-840. PMID: 40622436 -
J Int Med Res
Identification and validation of a seven cuproptosis-associated lncRNA signature to predict the prognosis of endometrial cancer. [Abstract]2023 Dec;51(12):3000605231213435. PMID: 38102991 -
Curr Med Sci
DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma. [Abstract]2023 Jun;43(3):526-538. PMID: 37286711 -
-
bioRxiv
Distinct control of T cell proliferation and effector function by partitioning of intracellular sulfur from cysteine. [Abstract]2026 Jan 29:2026.01.27.702014. PMID: 41659672 -
bioRxiv
Copper deficiency disrupts OXPHOS and mitochondrial dynamics through MTCH2-dependent copper trafficking in skeletal muscle. [Abstract]2025 Nov 19:2025.11.19.688750. PMID: 41332672 -
-
-
-
-
-
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (249.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (12.48 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 0.5% CMC/saline water
Solubility: 1 mg/mL (2.50 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Peter Tsvetkov, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022 Mar 18;375(6586):1254-1261. [Content Brief]
[2]. Peter Tsvetkov, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul;15(7):681-689. [Content Brief]
[3]. Kirshner JR, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008 Aug;7(8):2319-27. [Content Brief]
[4]. Liam M Guthrie, et al. Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice. Science. 2020 May 8;368(6491):620-625. [Content Brief]
[5]. Bair JS, et al. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J Am Chem Soc. 2010 Apr 21;132(15):5469-7 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4968 mL | 12.4838 mL | 24.9677 mL | 62.4192 mL |
| 5 mM | 0.4994 mL | 2.4968 mL | 4.9935 mL | 12.4838 mL | |
| 10 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL | 6.2419 mL | |
| 15 mM | 0.1665 mL | 0.8323 mL | 1.6645 mL | 4.1613 mL | |
| 20 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL | 3.1210 mL | |
| 25 mM | 0.0999 mL | 0.4994 mL | 0.9987 mL | 2.4968 mL | |
| 30 mM | 0.0832 mL | 0.4161 mL | 0.8323 mL | 2.0806 mL | |
| 40 mM | 0.0624 mL | 0.3121 mL | 0.6242 mL | 1.5605 mL | |
| 50 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2484 mL | |
| 60 mM | 0.0416 mL | 0.2081 mL | 0.4161 mL | 1.0403 mL | |
| 80 mM | 0.0312 mL | 0.1560 mL | 0.3121 mL | 0.7802 mL | |
| 100 mM | 0.0250 mL | 0.1248 mL | 0.2497 mL | 0.6242 mL |